GILEAD SCIENCES INC (GIS.DE) Stock Price, Forecast & Analysis
Europe - FRA:GIS - US3755581036 - Common Stock
GIS.DE Key Statistics, Chart & Performance
The current stock price of GIS.DE is 105.72 EUR. In the past month the price increased by 2.18%. In the past year, price increased by 21.93%.
GIS.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 71.64 | 47.37B | ||
| 1AE.DE | ARGENX SE | 69.42 | 45.91B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.63B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.01B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.25B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.86B | ||
| 5CV.DE | CUREVAC NV | 5.19 | 1.02B | ||
| NANO.PA | NANOBIOTIX | N/A | 872.70M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M | ||
| IVA.PA | INVENTIVA SA | N/A | 495.92M | ||
| FYB.DE | FORMYCON AG | N/A | 383.88M | ||
| VLA.PA | VALNEVA SE | N/A | 339.80M |
Related stock screener links
About GIS.DE
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17600
Phone: 16505743000
GILEAD SCIENCES INC / GIS.DE FAQ
What does GIS do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
Can you provide the latest stock price for GILEAD SCIENCES INC?
The current stock price of GIS.DE is 105.72 EUR. The price increased by 1.61% in the last trading session.
Does GILEAD SCIENCES INC pay dividends?
GILEAD SCIENCES INC (GIS.DE) has a dividend yield of 2.56%. The yearly dividend amount is currently 2.72.
What is the ChartMill technical and fundamental rating of GIS stock?
GIS.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is GILEAD SCIENCES INC (GIS.DE) stock traded?
GIS.DE stock is listed on the Deutsche Boerse Ag exchange.
What do analysts say about GILEAD SCIENCES INC (GIS.DE) stock?
36 analysts have analysed GIS.DE and the average price target is 113.8 EUR. This implies a price increase of 7.64% is expected in the next year compared to the current price of 105.72.
What is the expected growth for GIS stock?
The Revenue of GILEAD SCIENCES INC (GIS.DE) is expected to grow by 2.59% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
GIS.DE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GIS.DE. When comparing the yearly performance of all stocks, GIS.DE is one of the better performing stocks in the market, outperforming 74.53% of all stocks.
GIS.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GIS.DE. While GIS.DE has a great profitability rating, there are some minor concerns on its financial health.
GIS.DE Financial Highlights
Over the last trailing twelve months GIS.DE reported a non-GAAP Earnings per Share(EPS) of 7.08. The EPS increased by 84.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.88% | ||
| ROA | 13.86% | ||
| ROE | 37.8% | ||
| Debt/Equity | 0 |
GIS.DE Forecast & Estimates
36 analysts have analysed GIS.DE and the average price target is 113.8 EUR. This implies a price increase of 7.64% is expected in the next year compared to the current price of 105.72.
For the next year, analysts expect an EPS growth of 80.38% and a revenue growth 2.59% for GIS.DE